TY - JOUR
T1 - Applications of advances in mRNA-based platforms as therapeutics and diagnostics in reproductive technologies
AU - Bafleh, Wjdan S.
AU - Abdulsamad, Haia M.R.
AU - Al-Qaraghuli, Sally M.
AU - El Khatib, Riwa Y.
AU - Elbahrawi, Rawdah Taha
AU - Abdukadir, Azhar Mohamud
AU - Alsawae, Shaima M.
AU - Dimassi, Zakia
AU - Hamdan, Hamdan
AU - Kashir, Junaid
N1 - Publisher Copyright:
Copyright © 2023 Bafleh, Abdulsamad, Al-Qaraghuli, El Khatib, Elbahrawi, Abdukadir, Alsawae, Dimassi, Hamdan and Kashir.
PY - 2023
Y1 - 2023
N2 - The recent COVID-19 pandemic led to many drastic changes in not only society, law, economics, but also in science and medicine, marking for the first time when drug regulatory authorities cleared for use mRNA-based vaccines in the fight against this outbreak. However, while indeed representing a novel application of such technology in the context of vaccination medicine, introducing RNA into cells to produce resultant molecules (proteins, antibodies, etc.) is not a novel principle. It has been common practice to introduce/inject mRNA into oocytes and embryos to inhibit, induce, and identify several factors in a research context, while such aspects have also been proposed as potential therapeutic and diagnostic applications to combat infertility in humans. Herein, we describe key areas where mRNA-based platforms have thus far represented potential areas of clinical applications, describing the advantages and limitations of such applications. Finally, we also discuss how recent advances in mRNA-based platforms, driven by the recent pandemic, may stand to benefit the treatment of infertility in humans. We also present brief future directions as to how we could utilise recent and current advancements to enhance RNA therapeutics within reproductive biology, specifically with relation to oocyte and embryo delivery.
AB - The recent COVID-19 pandemic led to many drastic changes in not only society, law, economics, but also in science and medicine, marking for the first time when drug regulatory authorities cleared for use mRNA-based vaccines in the fight against this outbreak. However, while indeed representing a novel application of such technology in the context of vaccination medicine, introducing RNA into cells to produce resultant molecules (proteins, antibodies, etc.) is not a novel principle. It has been common practice to introduce/inject mRNA into oocytes and embryos to inhibit, induce, and identify several factors in a research context, while such aspects have also been proposed as potential therapeutic and diagnostic applications to combat infertility in humans. Herein, we describe key areas where mRNA-based platforms have thus far represented potential areas of clinical applications, describing the advantages and limitations of such applications. Finally, we also discuss how recent advances in mRNA-based platforms, driven by the recent pandemic, may stand to benefit the treatment of infertility in humans. We also present brief future directions as to how we could utilise recent and current advancements to enhance RNA therapeutics within reproductive biology, specifically with relation to oocyte and embryo delivery.
KW - calcium
KW - embryo
KW - oocyte
KW - oocyte activation
KW - RNA
KW - sperm
KW - therapeutics
UR - http://www.scopus.com/inward/record.url?scp=85161421371&partnerID=8YFLogxK
U2 - 10.3389/fcell.2023.1198848
DO - 10.3389/fcell.2023.1198848
M3 - Review article
AN - SCOPUS:85161421371
SN - 2296-634X
VL - 11
JO - Frontiers in Cell and Developmental Biology
JF - Frontiers in Cell and Developmental Biology
M1 - 1198848
ER -